SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1987 |
Sector | Life Science |
Employees | 3,726 |
Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas.
DEAL STATS | # |
---|---|
Overall | 1 of 7 |
Sector (Life Science) | 1 of 7 |
Type (Merger) | 1 of 1 |
State (Utah) | 1 of 1 |
Country (United States) | 1 of 4 |
Year (2000) | 1 of 1 |
Size (of disclosed) | 2 of 6 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2005-06-14 |
Salmedix
San Diego, California, United States Salmedix was a late stage biopharmaceutical company focusing on in-licensing and development of cancer products. The Company?s lead product, SDX-105, was in Phase II/III clinical trials for non-Hodgkin?s lymphoma at the time of Easton's investment. In addition, Salmedix had two drugs in Phase II clinical development, as well as several preclinical product candidates. |
Buy | $160M |